Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This review highlights the increased risk of cardiovascular disease and the dismal prognosis after acute coronary events when diabetes is present. Although there have been improvements in this area, diabetes still confers an increased risk. In order to achieve successful outcomes in individuals with diabetes, extensive treatment of risk factors and the use of all available evidence-based therapies are needed. In this context, glucose-lowering therapies and antithrombotic and revascularisation strategies are detailed in this review. Emerging data indicate that novel glucose-lowering drugs may impact cardiovascular outcome with mechanisms that are beyond glucose control. In addition, this review addresses hidden diabetes and impaired glucose tolerance in patients with acute and stable coronary artery disease and how they influence future cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Strategies for Multivessel Revascularization in Patients with Diabetes
Farkouh, M. E., Domanski, M., Sleeper, L. A., Siami, F. S., Dangas, G., Mack, M., Yang, M., Cohen, D. J., Rosenberg, Y., Solomon, S. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211585 · Cited by 1,922 · cited 5×
“Since the evidence is sparse, the most recent guidelines on revascularisation state that the assessment of viability should not be the sole factor when deciding on the best strategy for patients with severe left ventricular function and evident CAD.(39) Lifestyle intervention”
InfluentialNorhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112
Self-citationMalmberg, K., Rydén, L., Wedel, H., Birkeland, K., Bootsma, A., Dickstein, K., Efendic, S., Fisher, M., Hamsten, A., Herlitz, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi199 · Cited by 1,048
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
BARTNIK, M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.07.027 · Cited by 617
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492 · cited 1×
“Both of these drugs have the disadvantage of being associated with an increased risk of severe hypoglycaemia, which may contribute to cardiac complications and arrhythmia.(11,30,31) Novel classes of glucose-lowering agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists and…”
Cited by
Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755531 · Cited by 160
Cellular senescence links aging and diabetes in cardiovascular disease
Shakeri, H., Lemmens, K., Gevaert, A. B., De Meyer, G. R. Y., & Segers, V. F. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00287.2018 · Cited by 134
“In patients, high glucose levels and lipid concentrations remain independent risk factors for the development of atherosclerosis (14, 138).”
BackgroundSocio-Economic Inequity: Diabetes in New Zealand
Holder-Pearson, L., & Chase, J. G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.756223 · Cited by 38
Metadata
- Authors
- Norhammar, A., Mellbin, L., & Cosentino, F.
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06
- Volume
- 24
- Issue
- 3_suppl
- Pages
- 52-60
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2625231705
- Cited by
- 49
- References
- 11
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. https://app.cochat.ai/papers/10.1177/2047487317709554
- The paper
- Norhammar, A., Mellbin, L., & Cosentino, F. (2017). Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487317709554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.